HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Jing Yi Selected Research

Hemorrhagic Fever with Renal Syndrome (HFRS)

4/2015Hantaan virus infection induces both Th1 and ThGranzyme B+ cell immune responses that associated with viral control and clinical outcome in humans.
2/2015IL-33/ST2 correlates with severity of haemorrhagic fever with renal syndrome and regulates the inflammatory response in Hantaan virus-infected endothelial cells.
7/2014Increased plasma cell-free DNA level during HTNV infection: correlation with disease severity and virus load.
1/2014Hantaan virus infection induces CXCL10 expression through TLR3, RIG-I, and MDA-5 pathways correlated with the disease severity.
5/2013Hantaan virus RNA load in patients having hemorrhagic fever with renal syndrome: correlation with disease severity.
1/2013Elevated plasma soluble Sema4D/CD100 levels are associated with disease severity in patients of hemorrhagic fever with renal syndrome.
1/2013HLA-A2 and B35 restricted hantaan virus nucleoprotein CD8+ T-cell epitope-specific immune response correlates with milder disease in hemorrhagic fever with renal syndrome.
1/2012Sustained high level of serum VEGF at convalescent stage contributes to the renal recovery after HTNV infection in patients with hemorrhagic fever with renal syndrome.
1/2012The genetic polymorphisms of HLA are strongly correlated with the disease severity after Hantaan virus infection in the Chinese Han population.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Jing Yi Research Topics

Disease

22Neoplasms (Cancer)
06/2015 - 02/2002
9Hemorrhagic Fever with Renal Syndrome (HFRS)
04/2015 - 01/2012
7Carcinoma (Carcinomatosis)
02/2013 - 04/2002
5Prostatic Neoplasms (Prostate Cancer)
06/2015 - 03/2006
5Infection
05/2015 - 01/2012
5Gallbladder Neoplasms (Gallbladder Cancer)
01/2014 - 04/2010
5Leukemia
04/2010 - 01/2002
3Wounds and Injuries (Trauma)
07/2014 - 01/2002
3Glioma (Gliomas)
04/2009 - 07/2007
3Colorectal Neoplasms (Colorectal Cancer)
01/2009 - 09/2008
2Anoxia (Hypoxia)
05/2015 - 03/2008
2Stomach Neoplasms (Stomach Cancer)
08/2014 - 01/2008
2Fever (Fevers)
07/2014 - 01/2012
2Communicable Diseases (Infectious Diseases)
01/2014 - 01/2013
2Inflammation
01/2014 - 01/2009
2Squamous Cell Carcinoma (Epidermoid Carcinoma)
01/2013 - 09/2007
2Neoplasm Metastasis (Metastasis)
03/2012 - 09/2010
2Acute Promyelocytic Leukemia
11/2008 - 03/2008
1Insulin Resistance
11/2015
1Facial Paralysis (Facial Palsy)
05/2015
1Bell Palsy (Bell's Palsy)
05/2015
1Acute Kidney Injury (Acute Renal Failure)
05/2015
1Fatty Liver
02/2015
1Alcoholic Fatty Liver
02/2015
1Diabetic Nephropathies (Diabetic Nephropathy)
02/2015
1End Stage Liver Disease
01/2015
1Atherosclerotic Plaque (Atheroma)
01/2014
1Hepatic Encephalopathy
05/2013
1Coma (Comas)
05/2013
1Biliary Tract Neoplasms (Biliary Tract Cancer)
02/2013
1Multiple Myeloma
01/2013
1Neuralgia (Stump Neuralgia)
01/2013
1Hypertension (High Blood Pressure)
01/2013
1Fatigue
01/2013

Drug/Important Bio-Agent (IBA)

11Reactive Oxygen Species (Oxygen Radicals)IBA
02/2013 - 02/2002
9Emodin (Archin)IBA
02/2013 - 01/2004
7arsenic trioxide (Trisenox)FDA Link
11/2008 - 01/2002
6bevacizumabFDA Link
01/2013 - 09/2008
5ArsenicIBA
11/2008 - 12/2004
4Carbon MonoxideIBA
02/2013 - 03/2008
4Cisplatin (Platino)FDA LinkGeneric
02/2013 - 03/2008
4Aligeron (AS 2)IBA
06/2006 - 01/2002
3CytokinesIBA
02/2015 - 03/2010
3PlatinumIBA
02/2013 - 04/2010
3Carboplatin (JM8)FDA LinkGeneric
06/2012 - 04/2010
3panaxydolIBA
04/2009 - 07/2007
2Insulin (Novolin)FDA Link
11/2015 - 01/2009
2MicroRNAs (MicroRNA)IBA
11/2015 - 02/2015
2GossypolIBA
06/2015 - 09/2010
2Proteins (Proteins, Gene)IBA
06/2015 - 09/2010
2T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA
04/2015 - 01/2013
2CreatinineIBA
02/2015 - 01/2012
2BilirubinIBA
01/2015 - 05/2013
2Transcription Factors (Transcription Factor)IBA
08/2014 - 12/2008
2DNA (Deoxyribonucleic Acid)IBA
07/2014 - 01/2002
2AntigensIBA
01/2012 - 03/2010
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2012 - 11/2008
2Fluorouracil (Carac)FDA LinkGeneric
01/2009 - 09/2008
2NADPH Oxidase (NAD(P)H oxidase)IBA
11/2008 - 03/2008
2NF-kappa B (NF-kB)IBA
09/2007 - 06/2006
2Prostate-Specific Antigen (Semenogelase)IBA
04/2007 - 03/2006
1Insulin ReceptorIBA
11/2015
1apogossypolIBA
06/2015
1KP372-1IBA
05/2015
1NAD (NADH)IBA
05/2015
1Scavenger Receptors (Scavenger Receptor)IBA
05/2015
1U 0126 (UO 126)IBA
05/2015
1Aquaporin 1IBA
05/2015
1Glycoproteins (Glycoprotein)IBA
04/2015
1Toll-Like Receptor 2IBA
02/2015
1ShenshuainingIBA
02/2015
1telmisartan (Micardis)FDA Link
02/2015
1Cystatin CIBA
01/2015
1GTP-Binding Proteins (G-Protein)IBA
04/2014
1leucine receptorIBA
04/2014
1atorvastatin (Lipitor)FDA Link
01/2014
1glucuronyl glucosamine glycan sulfate (Vessel)IBA
01/2014
1myeloid cell leukemia sequence 1 proteinIBA
01/2014
1ChemokinesIBA
01/2014
1Alanine Transaminase (SGPT)IBA
05/2013
1NeuropeptidesIBA
05/2013
1gamma-Glutamyltransferase (gamma-Glutamyl Transpeptidase)IBA
05/2013
1AmmoniaIBA
05/2013
1RNA (Ribonucleic Acid)IBA
05/2013
1ornithylaspartateIBA
05/2013
1Naloxone (Narcan)FDA LinkGeneric
05/2013
1beta-Endorphin (Endorphin, beta)IBA
05/2013
1Arginine Vasopressin (Argipressin)IBA
05/2013
1multidrug resistance-associated protein 1IBA
02/2013
1Glutathione (Reduced Glutathione)IBA
02/2013
1Verapamil (Calan)FDA LinkGeneric
02/2013
1AmberIBA
01/2013
1Proteasome Endopeptidase Complex (Proteasome)IBA
01/2013
1bortezomib (Velcade)FDA Link
01/2013
1HLA-A2 Antigen (HLA A2 Antigen)IBA
01/2013
1CD100 antigenIBA
01/2013
1NucleoproteinsIBA
01/2013

Therapy/Procedure

10Drug Therapy (Chemotherapy)
06/2015 - 03/2008
4Heterologous Transplantation (Xenotransplantation)
06/2015 - 11/2008
1Aftercare (After-Treatment)
05/2013